Hospital Software As A Medical Device (SaMD) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Hospital Software As A Medical Device (SaMD) Market Trends and Insights

Rising Hospital Adoption of AI-Based Clinical Decision Making

The hospital software as a medical device (SaMD) market is benefiting from the rising adoption of AI tools that integrate directly into daily care pathways. Hospitals are prioritizing platforms that flag risk, support clinical prioritization, and fit into clinician workflows without adding extra steps. Procurement teams are also seeking evidence that software can influence treatment decisions, not just improve technical accuracy. Tempus AI reported that its ALERT trial across 35 hospitals and five US health systems improved treatment rates for significant valvular heart disease, with patients in the alert group 27% more likely to receive a multidisciplinary heart team evaluation and valve procedures increasing by 40% compared with usual care.

Expansion of Remote Monitoring and Virtual Ward Workflows

The hospital software as a medical device (SaMD) market is also gaining from the expansion of hospital-at-home and virtual ward models. These programs require software that can process remote patient data, detect deterioration early, and send timely alerts to care teams. A 2025 longitudinal analysis showed that NHS England had expanded virtual ward capacity to more than 12,600 beds by January 2025, with occupancy nearing 80%, indicating a larger installed need for monitoring software in formal care pathways. A multicenter UK cardiac study also found that remote monitoring for pre-surgical coronary artery bypass patients maintained clinical outcomes while reducing preoperative bed occupancy.

Hospital Pressure to Reduce Length of Stay and Readmissions

Hospitals face increasing pressure to improve patient throughput without compromising safety, which is supporting the hospital software as a medical device (SaMD) market. Software that triages scans, pre-fills reports, or detects deterioration earlier can influence bed use, discharge timing, and escalation decisions. This capability is critical in emergency care, imaging, and high-acuity settings, where delayed findings can slow patient flow. Vendors that can link their software to shorter stays or fewer readmissions are likely to gain stronger traction in hospital buying decisions.

PCCP-Enabled Iteration of AI Models After Market Clearance

The hospital software as a medical device (SaMD) market is also benefiting from a more usable pathway for post-clearance model updates in the United States. The FDA’s Predetermined Change Control Plan (PCCP) guidance allows manufacturers to propose certain future modifications in advance, reducing the need for a new marketing submission for each eligible update. This is important as hospitals do not want software to become outdated during repeated review cycles. Over time, this is expected to widen the gap between vendors that support continuous upgrades and those operating on slower release cycles.

Complex and Fragmented Regulatory Classification Pathways

The hospital software as a medical device (SaMD) market continues to face complex and fragmented regulatory pathways across major regions. In Europe, vendors must manage medical device regulations and AI-specific obligations, increasing documentation requirements and extending approval timelines. Germany’s Federal Commissioner for Data Protection and Freedom of Information and the Bundesnetzagentur issued a joint roadmap in July 2026 to help manufacturers navigate AI in medical devices, underscoring the compliance burden for vendors. Multi-country suppliers also face challenges as data handling, quality management, and clinical evidence expectations vary by market, slowing launches and favoring vendors with larger regulatory teams and stronger local partnerships.

Hospital IT Interoperability and Cybersecurity Burden

The hospital software as a medical device (SaMD) market also faces deployment challenges within hospital IT environments. Many hospitals operate PACS, RIS, LIS, EHR, and monitoring systems implemented at different times, making integration complex even for cleared products. Cybersecurity reviews further extend deployment timelines as hospitals require assurance on software updates, data flows, user access, and vendor support obligations. As a result, adoption moves faster in hospitals with stronger digital infrastructure and slower where integration represents a significant share of project costs.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Delivery Mode: Cloud Consolidation Accelerates Enterprise SaMD Adoption

Cloud-based deployment accounted for 69.55% of the hospital software as a medical device (SaMD) market size in 2025, highlighting hospitals’ strong shift toward vendor-managed delivery. Cloud platforms reduced local infrastructure needs, simplified software updates across care sites, and supported heavier computing workloads for imaging and model retraining. As a result, the hospital software as a medical device (SaMD) market continued to favor enterprise subscriptions over isolated departmental installations. The cloud-based deployment segment is projected to expand at a CAGR of 21.93% through 2031, reflecting platform consolidation across hospital networks.

Aidoc’s April 2026 Series E funding round of USD 150 million brought its total funding above USD 500 million and supported wider deployment of its aiOS enterprise platform and further development of its CARE clinical foundation model. This move showed that suppliers were building for scale rather than single-use deployment within the hospital software as a medical device (SaMD) industry. However, on-premises deployment remained relevant for hospitals with stricter data residency rules or local control requirements for time-sensitive use cases. 

By Software Type: Diagnostic SaMD Leads but Monitoring Builds Fastest

Diagnostic SaMD held 44.22% of the hospital software as a medical device (SaMD) market share in 2025, maintaining its leading position across software categories. Imaging gave diagnostic tools a strong base, as hospitals already relied on software-assisted review, prioritization, and reporting in high-volume departments. These products also fit more naturally into existing clinical processes than newer categories that required new protocols or staffing adjustments. Monitoring and alerting SaMD is projected to be the fastest-growing software type, registering a CAGR of 22.67% through 2031, as hospitals expand remote observation and early warning use cases.

Reimbursement support also improved for selected use cases. CMS added HCPCS code G0680 in its April 2026 Hospital Outpatient Prospective Payment System update for software analysis of coronary artery calcium from chest CT scans, showing how payment pathways started aligning with validated clinical software. Clinical decision support software also advanced in cardiology and oncology, where hospitals sought more actionable guidance within record systems. This trend created a broader growth pathway for the hospital software as a medical device (SaMD) market beyond diagnostic interpretation alone.

By Application: Radiology Leads, Neurology Commands the Fastest Growth

Radiology and medical imaging accounted for 47.66% of the hospital software as a medical device (SaMD) market size in 2025, making it the largest application area. Imaging departments generated high data volumes, followed standardized workflows, and faced early staffing pressure, which pushed software adoption ahead of many other specialties. Hospitals also trusted tools that supported prioritization, contouring, planning, and scan setup because these use cases aligned with existing operating routines. This kept radiology at the center of the hospital software as a medical device (SaMD) market as other specialties advanced.

GE HealthCare received FDA 510(k) clearance in June 2026 for MIM Contour ProtégéAI+ 2.0, and Philips received FDA 510(k) clearance in 2026 for SmartHeart, which supported faster AI-enabled cardiac MR planning. Neurology is projected to record the fastest CAGR of 29.35% through 2031, supported by demand for stroke coordination, quantitative neuroimaging, and neurodegenerative disease analysis. This part of the hospital software as a medical device (SaMD) market expanded as hospitals sought faster response pathways for acute neurological events and longer-term tools for chronic disease management. 

By Technology: Rules-Based Software Dominant, AI/ML Closes the Gap

Rules-based software held 52.33% of the hospital software as a medical device (SaMD) market share in 2025, reflecting the large installed base of alert logic, structured pathways, and clinical support rules within hospital systems. Hospitals continued to use these tools because they were familiar, easier to validate, and less disruptive to existing governance models. In many environments, simple rules still managed a large share of routine checking, routing, and escalation tasks. At the same time, AI and machine learning are projected to expand at a CAGR of 22.33% through 2031.

The next phase of competition is likely to center on platforms that can move from narrow, single-task use cases toward broader clinical reasoning and orchestration. Aidoc said its CARE clinical foundation model received FDA clearance in 2026 for a multi-disease triage system in clinical imaging, marking an important step for broader model-based software deployment. Hybrid architectures will remain important because many hospitals still want a visible rules layer alongside machine-learning outputs. 

Geography Analysis

North America held 40.25% of the hospital software as a medical device (SaMD) market size in 2025, maintaining its leading regional position. The region benefited from a large base of cleared products, mature hospital IT systems, and strong commercial readiness for enterprise software deployment. Reimbursement was still evolving, but the outlook became more constructive for certain validated use cases. CMS added HCPCS code G0680 in April 2026 for software analysis of coronary artery calcium from chest CT scans, showing that payment frameworks started recognizing software as part of reimbursable clinical activity.

Europe remained a significant part of the hospital software as a medical device (SaMD) market, but a stricter compliance environment shaped its growth path. Hospitals and vendors had to address both device regulation and AI-related obligations, which increased market entry costs and slowed deployment in some cases. Germany’s joint July 2026 roadmap from the BfDI and Bundesnetzagentur gave manufacturers clearer guidance on how AI in medical devices would be treated in practice. Large suppliers such as Philips remained well positioned in Europe by combining hardware relationships, clinical workflow tools, and certified software offerings across multiple hospital departments.

Asia-Pacific is the fastest-growing region in the hospital software as a medical device (SaMD) market, with a projected 21.95% CAGR through 2031. Digital health investment, large patient volumes, and rising interest in cloud-native hospital systems support growth. Japan’s SaMD review pathway and India’s expanding digital health infrastructure are helping software adoption move beyond early pilots in selected hospital networks. This regional trend is also expanding into the Middle East and Africa, where GCC healthcare modernization programs support procurement interest, while South America remains at an earlier stage, with Brazil and Argentina as the main entry points.